#drug pricing

An unusual alliance among senators emerged in the push to allow for the importation of drugs from Canada and the United Kingdom.

The court sided with the hospitals, which challenged a $1.6 billion Trump-era cut to 340B Medicare reimbursements.

Several makers of hepatitis C drugs are limiting health care providers’ access to the 340B Drug Pricing Program’s discounts.

HIV, hepatitis and LGBTQ advocates lead the charge. Plus, a study suggests that long-acting injectable PrEP isn’t cost effective.

Yes! The Mark Cuban Cost Plus Drug Company sells cheaper generic drugs for diabetes, cancer, high blood pressure, HIV, hepatitis and more.

A letter from 124 patient groups urges the White House to make drugs more affordable—and spells out how it can do so.

The report found U.S. cancer patients spent $5.6 billion in out-of-pocket costs for cancer treatment in 2018.

Teva’s new version of TDF and emtricitabine doesn’t offer much of a price break, but that could come next spring.

Advocating for yourself is the best medicine.

A cancer diagnosis often means extreme financial stress—and fights with insurance providers.

A new lawsuit accuses the imprisoned hedge funder of blocking generic rivals of an AIDS-related drug.

Over 60 drugmakers raised prices an average of 5.8% on hundreds of drugs.

Oncologist wins Senate backing by a vote of 72 to 18.

“Overall, the candidates seemed well informed around HIV/AIDS issues.”

A look at what the law says about buying prescription drugs from Canada.

Insurance companies can no longer implement harmful co-pay accumulator policies.